Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Select your species
The results of this study showed for the first time that CpGs of the DLC1 (zeige DYNLL1 ELISA Kits)-v1 alternative promoter is frequently hypermethylated in tumors of meningeal origin.
Receptor tyrosine kinase (zeige RET ELISA Kits) activation of RhoA (zeige RHOA ELISA Kits) is mediated by AKT (zeige AKT1 ELISA Kits) phosphorylation of DLC1 (zeige DYNLL1 ELISA Kits).
Study suggests a mechanism for EZH2 (zeige EZH2 ELISA Kits)-H3K27me3 epigenetic repression of DLC1 (zeige DYNLL1 ELISA Kits) and multilayered regulation of DLC1 (zeige DYNLL1 ELISA Kits)/Rho/ROCK signaling by EZH2 (zeige EZH2 ELISA Kits), and advocated the significant pro-metastatic role of EZH2 (zeige EZH2 ELISA Kits) via repressing tumor and metastasis suppressors.
The results identify DLC1 (zeige DYNLL1 ELISA Kits) as an activator of white and brown adipocyte differentiation, and provide a molecular link between PPARgamma (zeige PPARG ELISA Kits) and Rho pathways.
DLC-1 (zeige DYNLL1 ELISA Kits) has a positive regulatory role in endothelial cell angiogenesis.
Subsequent studies have demonstrated that DLC-1 (zeige DYNLL1 ELISA Kits) is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 (zeige DYNLL1 ELISA Kits) as a potential tumor suppressor. [review]
Tumor suppressor genes deleted in liver cancer 1 (DLC1), F-box/WD-repeat-containing protein 7 (FBXW7 (zeige FBXW7 ELISA Kits)), and cadherin-6 (CDH6 (zeige CDH6 ELISA Kits)) were identified as presumed targets in Cholangiocarcinoma (CC).Inverse correlation between promoter methylation and expression suggested miR (zeige MLXIP ELISA Kits)-129-2 and members of the miR (zeige MLXIP ELISA Kits)-200 family (miR (zeige MLXIP ELISA Kits)-200a, miR (zeige MLXIP ELISA Kits)-200b, and miR (zeige MLXIP ELISA Kits)-429) as novel tumor suppressors and oncomiRs, respectively, in CC
it was demonstrated that the rs621554 polymorphism was correlated with DLC1 (zeige DYNLL1 ELISA Kits) expression at the mRNA level. These results suggested that the rs621554 polymorphism is associated with breast cancer susceptibility and prognosis, and may serve as a biomarker for breast cancer development and progression.
curcumin down-regulates the expression of Sp1 (zeige PSG1 ELISA Kits) to inhibit the expression of DNA methyltransferase 1 (zeige DNMT1 ELISA Kits), thus subsequently reducing hypermethylation of DLC1 (zeige DYNLL1 ELISA Kits) promoter to induce DLC1 (zeige DYNLL1 ELISA Kits) expression.
DLC-1 (zeige DYNLL1 ELISA Kits) acts as a tumor suppressor gene in HCC (zeige FAM126A ELISA Kits) by regulating the expression of RhoA (zeige RHOA ELISA Kits)/ROCK2 (zeige ROCK2 ELISA Kits)/ moesin (zeige MSN ELISA Kits).
DLC-1 has a positive regulatory role in endothelial cell angiogenesis.
studies demonstrate that TNS1 (zeige TNS1 ELISA Kits) binds to DLC1 and fine-tunes its RhoGAP (zeige ARHGAP1 ELISA Kits) activity toward RhoA (zeige RHOA ELISA Kits) and that the TNS1 (zeige TNS1 ELISA Kits)-DLC1-RhoA (zeige RHOA ELISA Kits) signaling axis is critical in regulating cellular functions that lead to angiogenesis
Loss of expression of only Dlc1 isoform 2 may be sufficient for the development of thymic tumors and metastasis.
Several genes and biochemical activities collaborate with the inactivation of DLC1 to give rise to cell transformation in MEFs, and the identified genes are relevant to human tumors with low DLC1 expression.
The Dlc1 deficient cells showed altered cytoskeleton structure, increased RhoA (zeige RHOA ELISA Kits) activity and cellular migration.
DLC-1-/- embryos had defects in the neural tube, brain, heart, and placenta
Our data validate DLC1 as a potent tumor suppressor gene and suggest that its loss creates a dependence on the RhoA (zeige RHOA ELISA Kits) pathway that may be targeted therapeutically.
This gene encodes a GTPase-activating protein (GAP) that is a member of the rhoGAP family of proteins which play a role in the regulation of small GTP-binding proteins. GAP family proteins participate in signaling pathways that regulate cell processes involved in cytoskeletal changes. This gene functions as a tumor suppressor gene in a number of common cancers, including prostate, lung, colorectal, and breast cancers. Multiple transcript variants due to alternative promoters and alternative splicing have been found for this gene.
Rho-GTPase-activating protein 7
, START domain-containing protein 12
, StAR-related lipid transfer (START) domain containing 12
, deleted in liver cancer 1 protein
, deleted in liver cancer 1 variant 2
, rho GTPase-activating protein 7
, rho-type GTPase-activating protein 7
, deleted in liver cancer 1
, deleted in liver cancer 1 protein homolog
, stAR-related lipid transfer protein 12
, rho GTPase-activating protein 7-like
, Deleted in liver cancer 1 protein homolog
, Rho-type GTPase-activating protein 7
, rho GTPase activating protein 7